Bempedoic Acid: The Evidence for Statin-Intolerant Patients

Bempedoic acid occupies a specific and increasingly important niche: patients who cannot tolerate statins due to muscle symptoms, but who still need meaningful LDL reduction. What makes it clinically significant is not just that it avoids statin-related muscle side effects — it’s that the CLEAR Outcomes trial demonstrated actual cardiovascular event reduction in statin-intolerant patients.

How bempedoic acid works

Bempedoic acid inhibits ATP-citrate lyase (ACL), an enzyme that operates upstream of HMG-CoA reductase — the same pathway statins target, but at an earlier step. The result is reduced cholesterol synthesis in the liver and compensatory upregulation of LDL receptors.

The CLEAR Outcomes trial — what it showed

CLEAR Outcomes specifically enrolled 13,970 patients with documented statin intolerance and cardiovascular disease or high cardiovascular risk.

• Bempedoic acid reduced LDL by approximately 21% vs placebo
• Major adverse cardiovascular events reduced by 13% relative to placebo
• Absolute risk reduction: 1.6 percentage points over 40 months
• Non-fatal heart attack reduced by 23%
• Benefit was consistent across pre-specified subgroups

CLEAR Outcomes was the first large cardiovascular outcomes trial for a non-statin, non-injectable cholesterol-lowering medication in statin-intolerant patients. Published in NEJM in 2023.

Who bempedoic acid is appropriate for

Statin-intolerant patients — the primary indication: Muscle pain, weakness, or other adverse effects that caused discontinuation — who remain at elevated cardiovascular risk.

Add-on for patients not at LDL goal: Can be added to maximally tolerated statin + ezetimibe. Provides approximately 15–20% additional LDL reduction before escalating to PCSK9 inhibitors. This is Step 3 in the 2022 ACC Expert Consensus escalation framework.

Fixed-dose combination with ezetimibe (Nexlizet): Produces LDL reductions of approximately 35–40% — substantially more than either drug alone. Useful as an intermediate step before PCSK9 inhibitors.

Side effects — what differentiates bempedoic acid

No muscle side effects — confirmed

In CLEAR Outcomes and CLEAR Harmony, rates of myopathy and myalgia were similar between bempedoic acid and placebo groups — mechanistically expected and clinically validated.

Uric acid elevation — the important caveat

Tendon warning

Bempedoic acid carries a labeled warning for tendon rupture, based on a small number of cases in clinical trials. The risk appears low, but patients should report any tendon pain or swelling promptly.

Bempedoic acid vs. other non-statin options